Tag
REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.
REIMAGINE 1 shows that once-weekly CagriSema significantly reduced HbA1c and bodyweight versus placebo in early type 2 diabetes, with mainly gastrointestinal adverse events and a mechanistically compelling incretin–amylin profile.
A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerabi
A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option fo
New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.
